Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Lumme Inc

  • Akshaya Shanmugam, Lumme Inc

Lumme is a digital therapeutics company developing a continuous health monitoring and intervention platform. Using our technology platform, we have clinically demonstrated significant patient behavior change during the treatment period. We have received $1.8M in government grants to use our technology platform to develop products that target the top 3 addictions grappling our nation today: smoking, alcohol, and diet. Our 1st product is a smoking cessation platform that has demonstrated the highest clinically reported quit rates of any commercially available product or service. This work is an outcome of research conducted at UMass Amherst, co-developed with the Yale Tobacco Treatment Clinic, and funded by the National Cancer Institute.

  • Date:Monday, February 11
  • Time:2:45 PM - 3:00 PM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23486
  • Goal for Presentation:Fund raising
  • Company Website:https://lumme-labs.com/
  • Company HQ City:Amherst
  • Company HQ State:Massachusetts
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:1,800,000
  • Previous and Current Investors:National Institutes of Health
  • CEO/Top Company Official:Akshaya Shanmuagm
  • Year Founded:2014
  • Main Therapeutic Focus:Digital Health
  • Lead Product in Development:Smoking cessation platform
  • Development Phase of Primary Product:Other/Not Applicable
Speakers
Akshaya Shanmugam
Lumme Inc
Back